Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill combo aims to tame bone marrow cancer

NCT ID NCT07340138

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects and how the drug moves through the body. If results are promising, larger studies may follow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pelabresib (a drug taken as a pill) added to ruxolitinib (another pill)
What this could lead to
If it works, this could point toward a better combination treatment for myelofibrosis, potentially improving symptoms or slowing the disease.
What could go wrong
This is a very early, small study (only 6 people) focused on safety. It may not show clear benefit, and side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) PRIMARY MYELOFIBROSIS (PMF)

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Kamogawa, Chiba, 296-8602, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 0030006, Japan

  • Novartis Investigative Site

    RECRUITING

    Kamakura, Kanagawa, 247-8533, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurashiki, Okayama-ken, 7108602, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138431, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Chūō, Yamanashi, 409-3898, Japan

  • Novartis Investigative Site

    RECRUITING

    Kumamoto, 862-8655, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.